ID int64 6 67 | author stringclasses 23
values | year int64 2.01k 2.02k | cancerType stringclasses 13
values | cellLine stringclasses 27
values | time int64 8 144 | coumarin stringclasses 2
values | coumarinDose float64 0.1 335 | viability float64 3.66 109 | viabilitySD float64 0.5 24.6 | viabilityN int64 2 6 | control float64 77.3 111 | controlSD float64 0.86 12.5 | controlN int64 2 6 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
66 | Shiran et al. | 2,021 | Breast | MDA-MB231 | 24 | Auraptene | 25 | 87.03 | 3.34 | 3 | 100 | 3.36 | 3 |
66 | Shiran et al. | 2,021 | Breast | MDA-MB231 | 24 | Auraptene | 50 | 84.07 | 2.59 | 3 | 100 | 3.36 | 3 |
66 | Shiran et al. | 2,021 | Breast | MDA-MB231 | 24 | Auraptene | 100 | 58.14 | 2.6 | 3 | 100 | 3.36 | 3 |
66 | Shiran et al. | 2,021 | Breast | MDA-MB231 | 24 | Auraptene | 200 | 41.48 | 1.48 | 3 | 100 | 3.36 | 3 |
38 | Khaghanzadeh et al. | 2,012 | Lung | A549 | 24 | Umbelliprenin | 10 | 91 | 1.4 | 3 | 94.68 | 1.69 | 3 |
38 | Khaghanzadeh et al. | 2,012 | Lung | A549 | 24 | Umbelliprenin | 20 | 80.27 | 1.97 | 3 | 94.68 | 1.69 | 3 |
38 | Khaghanzadeh et al. | 2,012 | Lung | A549 | 24 | Umbelliprenin | 50 | 68.7 | 2.25 | 3 | 94.68 | 1.69 | 3 |
38 | Khaghanzadeh et al. | 2,012 | Lung | A549 | 24 | Umbelliprenin | 100 | 51.49 | 8.16 | 3 | 94.68 | 1.69 | 3 |
38 | Khaghanzadeh et al. | 2,012 | Lung | A549 | 24 | Umbelliprenin | 200 | 9.22 | 1.12 | 3 | 94.68 | 1.69 | 3 |
38 | Khaghanzadeh et al. | 2,012 | Lung | A549 | 48 | Umbelliprenin | 10 | 86.31 | 1.97 | 3 | 97.31 | 1.97 | 3 |
38 | Khaghanzadeh et al. | 2,012 | Lung | A549 | 48 | Umbelliprenin | 20 | 76.97 | 5.35 | 3 | 97.31 | 1.97 | 3 |
38 | Khaghanzadeh et al. | 2,012 | Lung | A549 | 48 | Umbelliprenin | 50 | 64.56 | 4.22 | 3 | 97.31 | 1.97 | 3 |
38 | Khaghanzadeh et al. | 2,012 | Lung | A549 | 48 | Umbelliprenin | 100 | 18.63 | 1.12 | 3 | 97.31 | 1.97 | 3 |
38 | Khaghanzadeh et al. | 2,012 | Lung | A549 | 48 | Umbelliprenin | 200 | 9.13 | 1.4 | 3 | 97.31 | 1.97 | 3 |
38 | Khaghanzadeh et al. | 2,012 | Lung | A549 | 72 | Umbelliprenin | 10 | 88.65 | 1.7 | 3 | 96.28 | 2.81 | 3 |
38 | Khaghanzadeh et al. | 2,012 | Lung | A549 | 72 | Umbelliprenin | 20 | 79.33 | 4.5 | 3 | 96.28 | 2.81 | 3 |
38 | Khaghanzadeh et al. | 2,012 | Lung | A549 | 72 | Umbelliprenin | 50 | 57.06 | 10.99 | 3 | 96.28 | 2.81 | 3 |
38 | Khaghanzadeh et al. | 2,012 | Lung | A549 | 72 | Umbelliprenin | 100 | 19.56 | 1.4 | 3 | 96.28 | 2.81 | 3 |
38 | Khaghanzadeh et al. | 2,012 | Lung | A549 | 72 | Umbelliprenin | 200 | 10.82 | 2.53 | 3 | 96.28 | 2.81 | 3 |
38 | Khaghanzadeh et al. | 2,012 | Lung | QU-DB | 24 | Umbelliprenin | 10 | 94.82 | 2.01 | 3 | 93.1 | 0.86 | 3 |
38 | Khaghanzadeh et al. | 2,012 | Lung | QU-DB | 24 | Umbelliprenin | 20 | 89.36 | 4.2 | 3 | 93.1 | 0.86 | 3 |
38 | Khaghanzadeh et al. | 2,012 | Lung | QU-DB | 24 | Umbelliprenin | 50 | 81.69 | 3.44 | 3 | 93.1 | 0.86 | 3 |
38 | Khaghanzadeh et al. | 2,012 | Lung | QU-DB | 24 | Umbelliprenin | 100 | 54.59 | 12.93 | 3 | 93.1 | 0.86 | 3 |
38 | Khaghanzadeh et al. | 2,012 | Lung | QU-DB | 24 | Umbelliprenin | 200 | 32.18 | 6.32 | 3 | 93.1 | 0.86 | 3 |
38 | Khaghanzadeh et al. | 2,012 | Lung | QU-DB | 48 | Umbelliprenin | 10 | 90.8 | 3.16 | 3 | 91.66 | 2.29 | 3 |
38 | Khaghanzadeh et al. | 2,012 | Lung | QU-DB | 48 | Umbelliprenin | 20 | 87.06 | 2.58 | 3 | 91.66 | 2.29 | 3 |
38 | Khaghanzadeh et al. | 2,012 | Lung | QU-DB | 48 | Umbelliprenin | 50 | 66.09 | 2.01 | 3 | 91.66 | 2.29 | 3 |
38 | Khaghanzadeh et al. | 2,012 | Lung | QU-DB | 48 | Umbelliprenin | 100 | 31.6 | 10.91 | 3 | 91.66 | 2.29 | 3 |
38 | Khaghanzadeh et al. | 2,012 | Lung | QU-DB | 48 | Umbelliprenin | 200 | 10.91 | 4.31 | 3 | 91.66 | 2.29 | 3 |
38 | Khaghanzadeh et al. | 2,012 | Lung | QU-DB | 72 | Umbelliprenin | 10 | 86.2 | 5.17 | 3 | 91.95 | 2.58 | 3 |
38 | Khaghanzadeh et al. | 2,012 | Lung | QU-DB | 72 | Umbelliprenin | 20 | 79.02 | 6.32 | 3 | 91.95 | 2.58 | 3 |
38 | Khaghanzadeh et al. | 2,012 | Lung | QU-DB | 72 | Umbelliprenin | 50 | 72.12 | 5.45 | 3 | 91.95 | 2.58 | 3 |
38 | Khaghanzadeh et al. | 2,012 | Lung | QU-DB | 72 | Umbelliprenin | 100 | 27.58 | 11.78 | 3 | 91.95 | 2.58 | 3 |
38 | Khaghanzadeh et al. | 2,012 | Lung | QU-DB | 72 | Umbelliprenin | 200 | 5.74 | 2.29 | 3 | 91.95 | 2.58 | 3 |
39 | Rashidi et al. | 2,016 | Colon | HT-29 | 24 | Umbelliprenin | 36.4 | 50 | 3.615 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Colon | HT-29 | 48 | Umbelliprenin | 33.6 | 50 | 3.615 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Colon | HT-29 | 72 | Umbelliprenin | 37.1 | 50 | 3.615 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Breast | MCF-7 | 24 | Umbelliprenin | 40.8 | 50 | 3.615 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Breast | MCF-7 | 48 | Umbelliprenin | 36.04 | 50 | 3.615 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Breast | MCF-7 | 72 | Umbelliprenin | 55.8 | 50 | 3.615 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Glioma | A172 | 24 | Umbelliprenin | 51.9 | 50 | 3.615 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Glioma | A172 | 48 | Umbelliprenin | 37.9 | 50 | 3.615 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Glioma | A172 | 72 | Umbelliprenin | 43.6 | 50 | 3.615 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Colon | HT-29 | 24 | Umbelliprenin | 8.1 | 98.85 | 3.43 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Colon | HT-29 | 24 | Umbelliprenin | 16.3 | 98.28 | 4 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Colon | HT-29 | 24 | Umbelliprenin | 32.7 | 89.92 | 3.04 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Colon | HT-29 | 24 | Umbelliprenin | 68.2 | 71.29 | 3.42 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Colon | HT-29 | 24 | Umbelliprenin | 136.4 | 29.08 | 2.85 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Colon | HT-29 | 24 | Umbelliprenin | 272.8 | 15.39 | 3.05 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Colon | HT-29 | 48 | Umbelliprenin | 8.1 | 99.23 | 3.05 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Colon | HT-29 | 48 | Umbelliprenin | 16.3 | 89.92 | 3.61 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Colon | HT-29 | 48 | Umbelliprenin | 32.7 | 92.38 | 3.62 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Colon | HT-29 | 48 | Umbelliprenin | 68.2 | 64.06 | 4 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Colon | HT-29 | 48 | Umbelliprenin | 136.4 | 25.28 | 2.85 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Colon | HT-29 | 48 | Umbelliprenin | 272.8 | 18.63 | 2.85 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Colon | HT-29 | 72 | Umbelliprenin | 8.1 | 99.04 | 3.24 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Colon | HT-29 | 72 | Umbelliprenin | 16.3 | 95.62 | 2.09 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Colon | HT-29 | 72 | Umbelliprenin | 32.7 | 92.01 | 2.66 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Colon | HT-29 | 72 | Umbelliprenin | 68.2 | 76.8 | 8.75 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Colon | HT-29 | 72 | Umbelliprenin | 136.4 | 28.13 | 3.99 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Colon | HT-29 | 72 | Umbelliprenin | 272.8 | 10.83 | 2.66 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Breast | MCF-7 | 24 | Umbelliprenin | 8.1 | 100 | 6.89 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Breast | MCF-7 | 24 | Umbelliprenin | 16.3 | 97.82 | 4.72 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Breast | MCF-7 | 24 | Umbelliprenin | 32.7 | 98.91 | 4.17 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Breast | MCF-7 | 24 | Umbelliprenin | 68.2 | 59.52 | 6.17 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Breast | MCF-7 | 24 | Umbelliprenin | 136.4 | 41.74 | 1.99 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Breast | MCF-7 | 24 | Umbelliprenin | 272.8 | 20.14 | 1.81 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Breast | MCF-7 | 48 | Umbelliprenin | 8.1 | 98.91 | 7.98 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Breast | MCF-7 | 48 | Umbelliprenin | 16.3 | 98 | 7.98 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Breast | MCF-7 | 48 | Umbelliprenin | 32.7 | 93.1 | 2.35 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Breast | MCF-7 | 48 | Umbelliprenin | 68.2 | 64.79 | 1.81 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Breast | MCF-7 | 48 | Umbelliprenin | 136.4 | 30.82 | 1.6 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Breast | MCF-7 | 48 | Umbelliprenin | 272.8 | 16.87 | 1.99 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Breast | MCF-7 | 72 | Umbelliprenin | 8.1 | 98.18 | 8.89 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Breast | MCF-7 | 72 | Umbelliprenin | 16.3 | 96.37 | 9.8 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Breast | MCF-7 | 72 | Umbelliprenin | 32.7 | 94.55 | 9.8 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Breast | MCF-7 | 72 | Umbelliprenin | 68.2 | 89.83 | 6.89 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Breast | MCF-7 | 72 | Umbelliprenin | 136.4 | 53.72 | 4.17 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Breast | MCF-7 | 72 | Umbelliprenin | 272.8 | 17.96 | 2.9 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Glioma | A172 | 24 | Umbelliprenin | 8.5 | 96.54 | 7.56 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Glioma | A172 | 24 | Umbelliprenin | 17 | 98.28 | 2.58 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Glioma | A172 | 24 | Umbelliprenin | 34 | 93.02 | 1.84 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Glioma | A172 | 24 | Umbelliprenin | 68.2 | 71.52 | 5.37 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Glioma | A172 | 24 | Umbelliprenin | 136.4 | 46.71 | 11.07 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Glioma | A172 | 24 | Umbelliprenin | 272.8 | 23.55 | 3.5 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Glioma | A172 | 48 | Umbelliprenin | 8.5 | 100.96 | 4.24 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Glioma | A172 | 48 | Umbelliprenin | 17 | 96.99 | 6.08 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Glioma | A172 | 48 | Umbelliprenin | 34 | 90.62 | 7.56 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Glioma | A172 | 48 | Umbelliprenin | 68.2 | 71.15 | 5.9 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Glioma | A172 | 48 | Umbelliprenin | 136.4 | 32.05 | 2.58 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Glioma | A172 | 48 | Umbelliprenin | 272.8 | 10.44 | 2.02 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Glioma | A172 | 72 | Umbelliprenin | 8.5 | 98.19 | 10.7 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Glioma | A172 | 72 | Umbelliprenin | 17 | 93.49 | 7.19 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Glioma | A172 | 72 | Umbelliprenin | 34 | 89.7 | 11.07 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Glioma | A172 | 72 | Umbelliprenin | 68.2 | 68.57 | 10.15 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Glioma | A172 | 72 | Umbelliprenin | 136.4 | 41.91 | 3.32 | 3 | 100 | 2.29 | 3 |
39 | Rashidi et al. | 2,016 | Glioma | A172 | 72 | Umbelliprenin | 272.8 | 17.83 | 2.76 | 3 | 100 | 2.29 | 3 |
43 | Goodarzi et al. | 2,022 | Leukemia/Lymphoma | MT-2 | 48 | Umbelliprenin | 20 | 99.8 | 4.8 | 3 | 99.9 | 1.96 | 3 |
43 | Goodarzi et al. | 2,022 | Leukemia/Lymphoma | MT-2 | 48 | Umbelliprenin | 40 | 99.9 | 4.8 | 3 | 99.9 | 1.96 | 3 |
43 | Goodarzi et al. | 2,022 | Leukemia/Lymphoma | MT-2 | 48 | Umbelliprenin | 80 | 74.9 | 3.77 | 3 | 99.9 | 1.96 | 3 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.